Test filters

News

In the media

Press releases

Publications

Scientific articles

Statements

Stories

Videos

Viewpoints

Press Releases Translations

27 Feb 2026

L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif de l’Agence Européenne des Médicaments (EMA) en tant que traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil

Press releases

27 Feb 2026

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

News

20 Feb 2026

DNDi welcomes GHIT support for lead identification of a novel chemical series in the Eisai-led Chagas disease project

In the media

17 Feb 2026

Still no specific treatment for dengue despite global risk

The Sun

Press releases

10 Feb 2026

DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases

Statements

10 Feb 2026

Statement on Brazil’s draft National Action Plan for Antimicrobial Resistance

Scientific articles

9 Feb 2026

Repurposing oxfendazole for onchocerciasis: Population pharmacokinetics of a tablet formulation in healthy African adults

CPT: Pharmacometrics & Systems Pharmacology

In the media

8 Feb 2026

Neglected killer: Kala-azar disease surges in Kenya

France 24

Statements

3 Feb 2026

DNDi interventions at the 158^th Session of the WHO Executive Board

Scientific articles

3 Feb 2026

Evaluation of quality of care in Chagas disease cardiomyopathy

Global Heart

News

2 Feb 2026

Message on the passing of Professor Sir Nicholas White from DNDi Board Chair Dr Marie-Paule Kieny and DNDi Executive Director Dr Luis Pizarro

In the media

1 Feb 2026

Maladies négligées : un modèle qui tient ses promesses

Pharmaceutiques

In the media

31 Jan 2026

Kala-azar in India: Treading the last mile towards elimination

The Hindu

In the media

30 Jan 2026

Neglected tropical diseases: Hope to eliminate

Life360-Healthwise

In the media

30 Jan 2026

Kala-azar cases rise in Kajiado West, children most affected

The Standard

News

30 Jan 2026

Imperial and DNDi strengthen partnership to accelerate treatments for neglected diseases

International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif de l’Agence Européenne des Médicaments (EMA) en tant que traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

DNDi welcomes GHIT support for lead identification of a novel chemical series in the Eisai-led Chagas disease project

Still no specific treatment for dengue despite global risk

DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases

Statement on Brazil’s draft National Action Plan for Antimicrobial Resistance

Repurposing oxfendazole for onchocerciasis: Population pharmacokinetics of a tablet formulation in healthy African adults

Neglected killer: Kala-azar disease surges in Kenya

DNDi interventions at the 158^th Session of the WHO Executive Board

Evaluation of quality of care in Chagas disease cardiomyopathy

Message on the passing of Professor Sir Nicholas White from DNDi Board Chair Dr Marie-Paule Kieny and DNDi Executive Director Dr Luis Pizarro

Maladies négligées : un modèle qui tient ses promesses

Kala-azar in India: Treading the last mile towards elimination

Neglected tropical diseases: Hope to eliminate

Kala-azar cases rise in Kajiado West, children most affected

Imperial and DNDi strengthen partnership to accelerate treatments for neglected diseases

Learn more

Get in touch

Support us

Work with us